OGEN Quote, Financials, Valuation and Earnings

Matinas BioPharma Holdings has a net margin of -- compared to Oragenics's net margin of --. Oragenics's return on equity of -- beat Matinas BioPharma Holdings's return on equity of --.

Oragenics has a consensus price target of $1.00, signalling upside risk potential of 493.12%. On the other hand Matinas BioPharma Holdings has an analysts' consensus of -- which suggests that it could grow by 4155.32%. Given that Matinas BioPharma Holdings has higher upside potential than Oragenics, analysts believe Matinas BioPharma Holdings is more attractive than Oragenics.

Oragenics has a beta of 1.161, which suggesting that the stock is 16.138% more volatile than S&P 500. In comparison Matinas BioPharma Holdings has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.261%.

Oragenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Matinas BioPharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oragenics pays -- of its earnings as a dividend. Matinas BioPharma Holdings pays out -- of its earnings as a dividend.

Oragenics quarterly revenues are --, which are smaller than Matinas BioPharma Holdings quarterly revenues of --. Oragenics's net income of -$3.3M is higher than Matinas BioPharma Holdings's net income of -$4.3M. Notably, Oragenics's price-to-earnings ratio is -- while Matinas BioPharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oragenics is 1.05x versus 0.80x for Matinas BioPharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Oragenics's net margin of -49.65%. Oragenics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Oragenics has a consensus price target of $1.00, signalling upside risk potential of 493.12%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.71%. Given that Oragenics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Oragenics is more attractive than NovaBay Pharmaceuticals.

Oragenics has a beta of 1.161, which suggesting that the stock is 16.138% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Oragenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oragenics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Oragenics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Oragenics's net income of -$3.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Oragenics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oragenics is 1.05x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nanoviricides has a net margin of -- compared to Oragenics's net margin of --. Oragenics's return on equity of -- beat Nanoviricides's return on equity of --.

Oragenics has a consensus price target of $1.00, signalling upside risk potential of 493.12%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 392.42%. Given that Oragenics has higher upside potential than Nanoviricides, analysts believe Oragenics is more attractive than Nanoviricides.

Oragenics has a beta of 1.161, which suggesting that the stock is 16.138% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

Oragenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oragenics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Oragenics quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Oragenics's net income of -$3.3M is lower than Nanoviricides's net income of -$2M. Notably, Oragenics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oragenics is 1.05x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Oragenics's net margin of --. Oragenics's return on equity of -- beat Theriva Biologics's return on equity of --.

Oragenics has a consensus price target of $1.00, signalling upside risk potential of 493.12%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 1032.29%. Given that Theriva Biologics has higher upside potential than Oragenics, analysts believe Theriva Biologics is more attractive than Oragenics.

Oragenics has a beta of 1.161, which suggesting that the stock is 16.138% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Oragenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oragenics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Oragenics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Oragenics's net income of -$3.3M is higher than Theriva Biologics's net income of -$4.4M. Notably, Oragenics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oragenics is 1.05x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.